| Adulterants in illicit drugs: a review of empirical evidence C Cole, L Jones, J McVeigh, A Kicman, Q Syed, M Bellis Drug testing and analysis 3 (2), 89-96, 2011 | 279 | 2011 |
| Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis D Sagoe, J McVeigh, A Bjørnebekk, MS Essilfie, CS Andreassen, ... Substance abuse treatment, prevention, and policy 10, 1-19, 2015 | 194 | 2015 |
| Human enhancement drugs: The emerging challenges to public health. M Evans-Brown, J McVeigh, C Perkins, MA Bellis | 179 | 2012 |
| Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study VD Hope, J McVeigh, A Marongiu, M Evans-Brown, J Smith, A Kimergård, ... BMJ open 3 (9), e003207, 2013 | 147 | 2013 |
| Anabolic steroids in the UK: an increasing issue for public health J McVeigh, E Begley Drugs: Education, Prevention and Policy 24 (3), 278-285, 2017 | 133 | 2017 |
| Identifying a typology of men who use anabolic androgenic steroids (AAS) R Zahnow, J McVeigh, G Bates, V Hope, J Kean, J Campbell, J Smith International Journal of Drug Policy 55, 105-112, 2018 | 123 | 2018 |
| Anabolic steroids detected in bodybuilding dietary supplements–a significant risk to public health V Abbate, AT Kicman, M Evans‐Brown, J McVeigh, DA Cowan, C Wilson, ... Drug Testing and Analysis 7 (7), 609-618, 2015 | 121 | 2015 |
| The involvement of drugs and alcohol in drug-facilitated sexual assault: a systematic review of the evidence CM Beynon, C McVeigh, J McVeigh, C Leavey, MA Bellis Trauma, Violence, & Abuse 9 (3), 178-188, 2008 | 118 | 2008 |
| CUT: A Guide to Adulterants, Bulking Agents and Other Contaminants Found in Illicit Drugs C Cole, L Jones, J McVeigh, A Kicman, Q Syed, MA Bellis | 101* | 2010 |
| Optimal provision of needle and syringe programmes for injecting drug users: A systematic review L Jones, L Pickering, H Sumnall, J McVeigh, MA Bellis International Journal of Drug Policy 21 (5), 335-342, 2010 | 99 | 2010 |
| Social, policy, and public health perspectives on new psychoactive substances HR Sumnall, M Evans‐Brown, J McVeigh Drug testing and analysis 3 (7‐8), 515-523, 2011 | 96 | 2011 |
| Human enhancement drugs and the pursuit of perfection J McVEIGH, M Evans-Brown, MA Bellis Adicciones 24 (3), 185-190, 2012 | 91 | 2012 |
| Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study A Kimergård, J McVeigh Harm Reduction Journal 11, 1-13, 2014 | 90 | 2014 |
| Use of melanotan I and II in the general population M Evans-Brown, RT Dawson, M Chandler, J McVeigh BMJ 338, 2009 | 84 | 2009 |
| Pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM): a scoping review on PrEP service delivery and programming A Hillis, J Germain, V Hope, J McVeigh, MC Van Hout AIDS and Behavior 24, 3056-3070, 2020 | 82 | 2020 |
| A study of anabolic steroid use in the North West of England P Lenehan, M Bellis, J McVeigh Journal of Performance Enhancing Drugs 1, 57-70, 1996 | 79 | 1996 |
| A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids G Bates, E Begley, D Tod, L Jones, C Leavey, J McVeigh Journal of Health Psychology 24 (11), 1595-1612, 2019 | 75 | 2019 |
| Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK A Kimergård, J McVeigh BMJ open 4 (6), e005275, 2014 | 74 | 2014 |
| Problematic drug use, ageing and older people: trends in the age of drug users in northwest England CM Beynon, JIM McVEIGH, B Roe Ageing & Society 27 (6), 799-810, 2007 | 70 | 2007 |
| Adverse effects, health service engagement, and service satisfaction among anabolic androgenic steroid users R Zahnow, J McVeigh, J Ferris, A Winstock Contemporary Drug Problems 44 (1), 69-83, 2017 | 67 | 2017 |
Geoff BatesInstitute for Policy Research, University of BathVerified email at bath.ac.uk
